Format

Send to

Choose Destination
J Rheumatol. 2005 Dec;32(12):2477-80.

Scleroderma--developing measures of response.

Author information

1
University of California at Los Angeles, CA 90025, USA. defurst@mednet.ucla.edu

Abstract

The scleroderma research community continued its focus on the development and proper validation of the outcome measures for clinical trials in scleroderma during the special interest group meeting at OMERACT 7. Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma.

PMID:
16331791
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center